DK1104306T3 - Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf - Google Patents

Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf

Info

Publication number: DK1104306T3
Authority: DK; Denmark
Prior art keywords: methods; saponin adjuvants; cpg; preparations; immunostimulatory oligonucleotides
Prior art date: 1998-08-10

Application number

DK99939711T

Other languages

English (en)

Inventor

Charlotte A Kensil

Original Assignee

Antigenics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-10

Filing date

1999-08-06

Publication date

2006-05-22

1999-08-06 Application filed by Antigenics Inc filed Critical Antigenics Inc

2006-05-22 Application granted granted Critical

2006-05-22 Publication of DK1104306T3 publication Critical patent/DK1104306T3/da

Links

239000002671 adjuvant Substances 0.000 title abstract 4
239000001397 quillaja saponaria molina bark Substances 0.000 title abstract 3
229930182490 saponin Natural products 0.000 title abstract 3
150000007949 saponins Chemical class 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 2
238000002360 preparation method Methods 0.000 title 1
108091034117 Oligonucleotide Proteins 0.000 abstract 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 2
230000002708 enhancing effect Effects 0.000 abstract 2
230000003308 immunostimulating effect Effects 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
230000024932 T cell mediated immunity Effects 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
230000036039 immunity Effects 0.000 abstract 1
230000016784 immunoglobulin production Effects 0.000 abstract 1
230000004936 stimulating effect Effects 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Steroid Compounds (AREA)

DK99939711T 1998-08-10 1999-08-06 Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf DK1104306T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9591398P	1998-08-10	1998-08-10
US12860899P	1999-04-08	1999-04-08

Publications (1)

Publication Number	Publication Date
DK1104306T3 true DK1104306T3 (da)	2006-05-22

Family

ID=26790746

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99939711T DK1104306T3 (da)	1998-08-10	1999-08-06	Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf

Country Status (11)

Country	Link
US (2)	US7049302B1 (da)
EP (1)	EP1104306B1 (da)
JP (1)	JP4620251B2 (da)
AT (1)	ATE315405T1 (da)
AU (1)	AU773204C (da)
CA (1)	CA2340174C (da)
DE (1)	DE69929444T2 (da)
DK (1)	DK1104306T3 (da)
ES (1)	ES2257068T3 (da)
PT (1)	PT1104306E (da)
WO (1)	WO2000009159A1 (da)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030026782A1 (en)	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6589940B1 (en)	1997-06-06	2003-07-08	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20020147143A1 (en)	1998-03-18	2002-10-10	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
DK1077722T3 (da)	1998-05-22	2006-11-27	Ottawa Health Research Inst	Fremgangsmåder og produkter til induktion af mukosaimmunitet
ATE315405T1 (de) *	1998-08-10	2006-02-15	Antigenics Inc	Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
DE60044236D1 (de) *	1999-02-17	2010-06-02	Csl Ltd	Immunogene komplexe und methoden in bezug auf diese
US6558670B1 (en)	1999-04-19	2003-05-06	Smithkline Beechman Biologicals S.A.	Vaccine adjuvants
GB9908885D0 (en) *	1999-04-19	1999-06-16	Smithkline Beecham Biolog	Vccine
DK1187629T3 (da) *	1999-04-19	2005-01-17	Glaxosmithkline Biolog Sa	Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
DE60039715D1 (de) *	1999-11-19	2008-09-11	Csl Ltd	Hcv-impfstoff zusammensetzungen
CA2397374A1 (en) *	2000-01-13	2001-07-19	Antigenics Inc.	Innate immunity-stimulating compositions of cpg and saponin and methods thereof
SI1650221T1 (sl)	2000-02-23	2012-09-28	Glaxosmithkline Biolog Sa	Nove spojine
PT2133100E (pt)	2000-06-20	2012-01-11	Corixa Corp	Antigénio mtb32a de mycobacterium tuberculosis com um local activo inactivado e suas proteínas de fusão
EP1319069B1 (en)	2000-06-28	2008-05-21	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
UA79735C2 (uk)	2000-08-10	2007-07-25	Глаксосмітклайн Байолоджікалз С.А.	Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
ATE534401T1 (de) *	2000-10-18	2011-12-15	Glaxosmithkline Biolog Sa	Mage antigen gekoppelt an einem protein d fragment enthaltende impfstoffe
IL155282A0 (en) *	2000-10-18	2003-11-23	Glaxosmithkline Biolog Sa	Vaccines
CA2446788A1 (en)	2001-05-09	2002-11-14	Corixa Corporation	Compositions and methods for the therapy and diagnosis of prostate cancer
EP1450856B1 (en)	2001-09-14	2009-11-11	Cytos Biotechnology AG	Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
EP1581119B1 (en)	2001-12-17	2013-01-30	Corixa Corporation	Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US20060210555A1 (en) *	2001-12-21	2006-09-21	Antigenics, Inc.	Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
ATE489969T1 (de) *	2002-06-20	2010-12-15	Cytos Biotechnology Ag	Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
CN100421730C (zh) *	2002-07-10	2008-10-01	英特威国际有限公司	免疫原性组合物
US7956043B2 (en)	2002-12-11	2011-06-07	Coley Pharmaceutical Group, Inc.	5′ CpG nucleic acids and methods of use
EP1608403A2 (en) *	2003-04-02	2005-12-28	Coley Pharmaceutical Group, Ltd.	Immunostimulatory nucleic acid oil-in-water formulations for topical application
EP1708745B1 (en)	2003-12-23	2012-04-18	Arbor Vita Corporation	Antibodies for oncogenic strains of hpv and methods of their use
WO2005072290A2 (en) *	2004-01-23	2005-08-11	Joslin Diabetes Center	Methods of treating, reducing, or preventing autoimmune conditions
EP2269638A3 (en)	2004-05-28	2012-06-13	GlaxoSmithKline Biologicals S.A.	Vaccine compositions comprising virosomes and a saponin adjuvant
CN101184504A (zh)	2005-03-31	2008-05-21	葛兰素史密丝克莱恩生物有限公司	针对衣原体感染的疫苗
ES2539042T3 (es)	2006-06-02	2015-06-25	Glaxosmithkline Biologicals S.A.	Procedimiento de identificación de si un paciente será respondedor o no a inmunoterapia
US20090142362A1 (en) *	2006-11-06	2009-06-04	Avant Immunotherapeutics, Inc.	Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
WO2008124647A2 (en)	2007-04-04	2008-10-16	Infectious Disease Research Institute	Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
US8518903B2 (en)	2007-04-19	2013-08-27	University of Pittsburgh—of the Commonwealth System of Higher Education	Use of toll-like receptor-9 agonists
WO2008131074A1 (en)	2007-04-19	2008-10-30	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
CN101678091A (zh) *	2007-05-24	2010-03-24	葛兰素史密丝克莱恩生物有限公司	冷冻干燥的抗原组合物
NZ596545A (en)	2007-09-17	2013-05-31	Glaxosmithkline Biolog Sa	Improved detection of mage-a expression
ES2569907T3 (es)	2008-06-27	2016-05-13	Zoetis Services Llc	Composiciones adyuvantes novedosas
TW201010719A (en) *	2008-08-19	2010-03-16	Wyeth Corp	Immunological composition
BRPI0923225A2 (pt)	2008-12-02	2016-10-04	Chiralgen Ltd	metodo para sintese de acidos nucleicos modificados no atomo de fosforo
EP2381949B1 (en) *	2008-12-23	2012-11-21	Intervet International BV	Immunostimulating saponins for use in in situ tumor-destruction therapy
EP2202298A1 (en)	2008-12-23	2010-06-30	Stichting Dienst Landbouwkundig Onderzoek	Recombinant classical swine fever virus (CSFV) comprising a modified E2 protein and methods for generating said recombinant CSFV
BRPI1009873A2 (pt)	2009-03-17	2016-03-08	Glaxosmithkline Biolog Sa	detecção aperfeiçoada de expressão gênica
EP2451461A4 (en)	2009-07-06	2013-05-29	Ontorii Inc	NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
GB0917457D0 (en)	2009-10-06	2009-11-18	Glaxosmithkline Biolog Sa	Method
HRP20181039T1 (hr)	2010-05-28	2018-08-24	Zoetis Belgium S.A.	Cjepiva koja sadrže kolesterol i cpg kao jedine molekule koje nose adjuvans
US9072760B2 (en)	2010-09-24	2015-07-07	University of Pittsburgh—of the Commonwealth System of Higher Education	TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
US10668092B2 (en)	2010-09-24	2020-06-02	The John Hopkins University	Compositions and methods for treatment of inflammatory disorders
DK2620428T3 (da)	2010-09-24	2019-07-01	Wave Life Sciences Ltd	Asymmetrisk hjælpegruppe
US20130345079A1 (en)	2010-10-27	2013-12-26	Infectious Disease Research Institute	Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
EP2637687B1 (en)	2010-11-08	2021-01-06	Infectious Disease Research Institute	Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
WO2012088425A2 (en)	2010-12-22	2012-06-28	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
GB201106357D0 (en)	2011-04-14	2011-06-01	Pessi Antonello	Composition and uses thereof
JP2014527398A (ja)	2011-06-21	2014-10-16	オンコファクターコーポレイション	がんの療法および診断のための組成物および方法
CN107365339A (zh)	2011-07-19	2017-11-21	波涛生命科学有限公司	合成官能化核酸的方法
DK2872147T3 (da)	2012-07-13	2023-02-20	Wave Life Sciences Ltd	Fremgangsmåde til fremstilling af kirale oligonukleotider
WO2014010250A1 (en)	2012-07-13	2014-01-16	Chiralgen, Ltd.	Asymmetric auxiliary group
EP4299138A3 (en)	2012-08-03	2024-08-14	Access to Advanced Health Institute	Compositions and methods for treating an active mycobacterium tuberculosis infection
US9562066B2 (en)	2012-09-25	2017-02-07	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Oral therapy of necrotizing enterocolitis
EP2978447B1 (en)	2013-03-28	2019-05-08	Infectious Disease Research Institute	Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
KR20200039025A (ko)	2013-09-19	2020-04-14	조에티스 서비시즈 엘엘씨	유성 아쥬반트
EP3095461A4 (en) *	2014-01-15	2017-08-23	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
EP3095459A4 (en) *	2014-01-15	2017-08-23	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
WO2015108046A1 (ja) *	2014-01-15	2015-07-23	株式会社新日本科学	抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP3094728B1 (en)	2014-01-16	2022-03-09	Wave Life Sciences Ltd.	Chiral design
LT3148579T (lt)	2014-05-28	2021-05-25	Agenus Inc.	Anti-gitr antikūnai ir jų panaudojimo būdai
AR102547A1 (es)	2014-11-07	2017-03-08	Takeda Vaccines Inc	Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
AR102548A1 (es)	2014-11-07	2017-03-08	Takeda Vaccines Inc	Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
MX391930B (es)	2015-01-16	2025-03-21	Zoetis Services Llc	Vacuna contra la fiebre aftosa.
WO2016138164A1 (en) *	2015-02-26	2016-09-01	Thevax Genetics Vaccine Co., Ltd.	A vaccine composition comprising an immunogenic protein and combination adjuvants for use in eliciting antigen-specific t-cell responses
EP3294324A1 (en)	2015-05-13	2018-03-21	Agenus Inc.	Vaccines for treatment and prevention of cancer
US10682314B2 (en)	2015-05-26	2020-06-16	Ohio State Innovation Foundation	Nanoparticle based vaccine strategy against swine influenza virus
US10456459B2 (en)	2015-07-20	2019-10-29	Zoetis Services Llc	Liposomal adjuvant compositions
JP6869987B2 (ja)	2015-09-01	2021-05-12	アジェナスインコーポレイテッド	抗ｐｄ−１抗体及びその使用方法
WO2017096179A1 (en)	2015-12-02	2017-06-08	Agenus Inc.	Antibodies and methods of use thereof
EP3458088A2 (en)	2016-05-21	2019-03-27	Infectious Disease Research Institute	Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
KR102543118B1 (ko)	2016-05-27	2023-06-14	아게누스 인코포레이티드	항-tim-3 항체 및 이의 사용 방법
WO2018053294A1 (en)	2016-09-16	2018-03-22	Infectious Disease Research Institute	Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
KR20230133934A (ko)	2016-10-11	2023-09-19	아게누스 인코포레이티드	항-lag-3 항체 및 이의 사용 방법
AU2018207172B2 (en)	2017-01-13	2023-10-12	Mink Therapeutics, Inc.	T cell receptors that bind to NY-ESO-1 and methods of use thereof
BR112019017241A2 (pt)	2017-04-13	2020-04-14	Agenus Inc.	anticorpos anti-cd137 e métodos de uso dos mesmos
LT3618863T (lt)	2017-05-01	2023-10-10	Agenus Inc.	Anti-tigit antikūnai ir jų panaudojimo būdai
US11123415B2 (en)	2017-08-16	2021-09-21	Ohio State Innovation Foundation	Nanoparticle compositions for Salmonella vaccines
CN107537035A (zh) *	2017-08-30	2018-01-05	北京恩元华生物科技有限公司	复合佐剂及含复合佐剂的狂犬疫苗及其制备方法和应用
WO2019046856A1 (en)	2017-09-04	2019-03-07	Agenus Inc.	T-CELL RECEPTORS THAT BIND TO SPECIFIC PHOSPHOPEPTIDES OF MIXED LINEAR LEUKEMIA (MLL) AND METHODS OF USE THEREOF
MY202505A (en)	2017-11-03	2024-05-01	Takeda Vaccines Inc	Zika vaccines and immunogenic compositions, and methods of using the same
EP3784688A2 (en)	2018-04-26	2021-03-03	Agenus Inc.	Heat shock protein-binding peptide compositions and methods of use thereof
GB201901608D0 (en)	2019-02-06	2019-03-27	Vib Vzw	Vaccine adjuvant conjugates
CN114585644A (zh)	2019-08-30	2022-06-03	艾吉纳斯公司	抗cd96抗体及其使用方法
AU2020403296B2 (en) *	2019-12-13	2025-03-06	Grand Theravac Life Science (Nanjing) Co., Ltd.	Immunostimulatory composition and use thereof
CN113058033B (zh) *	2019-12-16	2024-07-09	远大赛威信生命科学(南京)有限公司	一种用于预防和治疗乙型肝炎的药物组合物及其用途
AU2021321944A1 (en)	2020-08-07	2023-04-06	Access To Advanced Health Institute	Purified saponins and chromatographic process for purification of same
WO2022226534A2 (en) *	2021-04-23	2022-10-27	Oakwood Laboratories, Llc	Microsphere formulations comprising multiple non-identical peptides and methods for making the same

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4469863A (en)	1980-11-12	1984-09-04	Ts O Paul O P	Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en)	1981-10-23	1991-06-11	Molecular Biosystems, Inc.	Oligonucleotide therapeutic agent and method of making same
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5352449A (en)	1986-05-30	1994-10-04	Cambridge Biotech Corporation	Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant
US5057540A (en)	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
US5583112A (en)	1987-05-29	1996-12-10	Cambridge Biotech Corporation	Saponin-antigen conjugates and the use thereof
US5650398A (en)	1992-07-02	1997-07-22	Cambridge Biotech Corporation	Drug delivery enhancement via modified saponins
US5273965A (en)	1992-07-02	1993-12-28	Cambridge Biotech Corporation	Methods for enhancing drug delivery with modified saponins
CA2172153C (en) *	1993-09-20	2010-03-09	John C. Reed	Regulation of bcl-2 gene expression
WO1995026204A1 (en)	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US6429199B1 (en) *	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
AU713040B2 (en) *	1994-07-15	1999-11-18	University Of Iowa Research Foundation, The	Immunomodulatory oligonucleotides
AUPM873294A0 (en)	1994-10-12	1994-11-03	Csl Limited	Saponin preparations and use thereof in iscoms
US6335018B1 (en) *	1995-05-01	2002-01-01	Aventis Pasteur Limited	High molecular weight major outer membrane protein of moraxella
US5968909A (en) *	1995-08-04	1999-10-19	Hybridon, Inc.	Method of modulating gene expression with reduced immunostimulatory response
US6231859B1 (en)	1996-12-02	2001-05-15	Aquila Biopharmaceuticals, Inc.	Saponin adjuvant compositions
CA2281838A1 (en) *	1997-02-28	1998-09-03	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU753688B2 (en)	1997-03-10	2002-10-24	Ottawa Civic Loeb Research Institute	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
NZ500779A (en)	1997-05-20	2001-06-29	Galenica Pharmaceuticals Inc	Triterpene saponin analogs having adjuvant and immunostimulatory activity
EP1003531B1 (en) *	1997-05-20	2007-08-22	Ottawa Health Research Institute	Processes for preparing nucleic acid constructs
WO1998055609A1 (en)	1997-06-06	1998-12-10	The Regents Of The University Of California	Inhibitors of dna immunostimulatory sequence activity
AU734180B2 (en)	1997-08-29	2001-06-07	Antigenics Llc	Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
US6013258A (en) *	1997-10-09	2000-01-11	Zycos Inc.	Immunogenic peptides from the HPV E7 protein
US6218371B1 (en) *	1998-04-03	2001-04-17	University Of Iowa Research Foundation	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
AU760795B2 (en)	1998-05-14	2003-05-22	Coley Pharmaceutical Gmbh	Methods for regulating hematopoiesis using CpG-oligonucleotides
DK1077722T3 (da) *	1998-05-22	2006-11-27	Ottawa Health Research Inst	Fremgangsmåder og produkter til induktion af mukosaimmunitet
US6562798B1 (en)	1998-06-05	2003-05-13	Dynavax Technologies Corp.	Immunostimulatory oligonucleotides with modified bases and methods of use thereof
ATE315405T1 (de) *	1998-08-10	2006-02-15	Antigenics Inc	Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
US20010034330A1 (en)	1998-08-10	2001-10-25	Charlotte Kensil	Innate immunity-stimulating compositions of CpG and saponin and methods thereof
CA2344558A1 (en)	1998-10-09	2000-04-20	Dynavax Technologies Corporation	Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
DK1187629T3 (da)	1999-04-19	2005-01-17	Glaxosmithkline Biolog Sa	Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
US6558670B1 (en)	1999-04-19	2003-05-06	Smithkline Beechman Biologicals S.A.	Vaccine adjuvants
IL155282A0 (en)	2000-10-18	2003-11-23	Glaxosmithkline Biolog Sa	Vaccines
US20030119774A1 (en) *	2001-09-25	2003-06-26	Marianna Foldvari	Compositions and methods for stimulating an immune response
AR045702A1 (es) *	2001-10-03	2005-11-09	Chiron Corp	Composiciones de adyuvantes.
KR20050048539A (ko) *	2001-10-06	2005-05-24	메리얼엘엘씨	ＣｐＧ 제제 및 관련된 방법
SE0301998D0 (sv) *	2003-07-07	2003-07-07	Isconova Ab	Quil A fraction with low toxicity and use thereof
GB0401239D0 (en) *	2004-01-21	2004-02-25	Molecularnature Ltd	Adjuvant compositions

1999
- 1999-08-06 AT AT99939711T patent/ATE315405T1/de active
- 1999-08-06 DK DK99939711T patent/DK1104306T3/da active
- 1999-08-06 JP JP2000564661A patent/JP4620251B2/ja not_active Expired - Lifetime
- 1999-08-06 AU AU53953/99A patent/AU773204C/en not_active Expired
- 1999-08-06 PT PT99939711T patent/PT1104306E/pt unknown
- 1999-08-06 EP EP99939711A patent/EP1104306B1/en not_active Expired - Lifetime
- 1999-08-06 ES ES99939711T patent/ES2257068T3/es not_active Expired - Lifetime
- 1999-08-06 CA CA2340174A patent/CA2340174C/en not_active Expired - Lifetime
- 1999-08-06 US US09/369,941 patent/US7049302B1/en not_active Expired - Lifetime
- 1999-08-06 DE DE69929444T patent/DE69929444T2/de not_active Expired - Lifetime
- 1999-08-06 WO PCT/US1999/017956 patent/WO2000009159A1/en not_active Ceased
2006
- 2006-03-10 US US11/373,806 patent/US7858589B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU773204B2 (en)	2004-05-20
JP2002522510A (ja)	2002-07-23
ATE315405T1 (de)	2006-02-15
WO2000009159A9 (en)	2000-07-27
DE69929444D1 (de)	2006-04-06
EP1104306A1 (en)	2001-06-06
AU5395399A (en)	2000-03-06
US20060177458A1 (en)	2006-08-10
CA2340174A1 (en)	2000-02-24
DE69929444T2 (de)	2006-09-28
US7858589B2 (en)	2010-12-28
US7049302B1 (en)	2006-05-23
WO2000009159A1 (en)	2000-02-24
EP1104306B1 (en)	2006-01-11
CA2340174C (en)	2011-01-04
ES2257068T3 (es)	2006-07-16
AU773204C (en)	2005-05-19
JP4620251B2 (ja)	2011-01-26
PT1104306E (pt)	2006-05-31

Publication	Publication Date	Title
PT1104306E (pt)	2006-05-31	Composicoes de cpg e adjuvantes de saponina e seus metodos
IS4518A (is)	1999-01-10	Nýtt lyfjaform fyrir bóluefni
EP1594536A4 (en)	2006-09-06	ADJUVANT INFLUENZA VACCINE
MY125202A (en)	2006-07-31	Vaccine
GB0123580D0 (en)	2001-11-21	Vaccine
DK1459766T3 (da)	2008-10-13	Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
NO20015073L (no)	2001-11-22	Vaksiner
PT865297E (pt)	2003-03-31	Composicoes de vacinas para administracao intranasal compreendendo quitosano e suas utilizacoes
MXPA01007760A (es)	2003-06-24	Compuesto adyuvante inmunologico.
WO2004030608A3 (en)	2005-03-10	Nanoemulsion vaccines
IL150602A (en)	2010-12-30	Proteosome influenza vaccine, method for preparing such and use thereof
MY125000A (en)	2006-07-31	Novel compositions
AU5162201A (en)	2001-10-30	Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
CY1112658T1 (el)	2016-02-10	Εμβολια τα οποια περιεχουν αντιγονο μαgε συνδεομενο με θραυσμα πρωτεϊνης d
GB2386072A (en)	2003-09-10	Novel vaccine
DE60226175D1 (de)	2008-05-29	Mycobakterieller impfstoff
ATE370745T1 (de)	2007-09-15	Verbesserte polysaccharid- und glykokonjugat- vakzine
AU2001284354A1 (en)	2002-02-13	Immunological adjuvant compounds, compositions, and methods of use thereof
WO2000050073A3 (en)	2001-02-22	Caulobacter lps immunoadjuvant
WO2001015727A3 (en)	2001-09-07	Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof
WO2000006198A3 (en)	2001-07-19	Adjuvant comprising pulmonary surfactant
DE69922212D1 (de)	2004-12-30	Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
MY127452A (en)	2006-12-29	Vaccines.
DK0952771T3 (da)	2008-05-19	Hidtil ukendte saponinpræparater og anvendelser deraf
DK1227840T3 (da)	2008-02-04	Adjuverede, genetiske vacciner